amg 223
Small moleculeexperimental
Clinical trial activity
14 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
8
Phase 3
5
Phase 4
0
Earliest trial started Oct 1, 2007 (NCT00505037)
Timeline
Indications
Studied for
- Chronic Kidney Disease-Mineral and Bone Disorder · Phase 2
- Healthy Volunteers · Phase 1
- Hyperphosphatemia · Phase 3
- Kidney Diseases · Phase 2
- Kidney Failure, Chronic · Phase 2
- Pharmacokinetics · Phase 1
- Phosphates · Phase 2
- Renal Dialysis · Phase 3
- Renal Insufficiency · Phase 3
- Renal Insufficiency, Chronic · Phase 3
- Urination Disorders · Phase 1
Mechanism of action
- Calcitonin gene-related peptide 1INHIBITOR
CALCA inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- amg 223
- amg 223
- asp1585
- asp1585
- bixalomer
- bixalomer
- kiklin
- kiklin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02531204 | Phase 1 | Aug 1, 2014 | Astellas |
| NCT01742611 | Phase 3 | Mar 1, 2013 | Astellas |
| NCT01742585 | Phase 3 | Oct 1, 2012 | Astellas |
| NCT01124747 | Phase 1 | Apr 1, 2010 | Astellas |
| NCT01115946 | Phase 1 | Mar 1, 2010 | Astellas |
| NCT01115972 | Phase 1 | Mar 1, 2010 | Astellas |
| NCT01115985 | Phase 1 | Mar 1, 2010 | Astellas |
| NCT01057407 | Phase 3 | Jan 1, 2010 | Astellas |
| NCT01017276 | Phase 3 | Nov 1, 2009 | Astellas |
| NCT00892749 | Phase 3 | May 1, 2009 | Astellas |
| NCT00756860 | Phase 1 | May 1, 2008 | Amgen |
| NCT00530114 | Phase 2 | Mar 1, 2008 | Amgen |
| NCT02753894 | Phase 2 | Jan 1, 2008 | Astellas |
| NCT00505037 | Phase 2 | Oct 1, 2007 | Astellas |
Showing 14 of 14 trials
Page 1 / 1